Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.

Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.

Item
http://www.wikidata.org/entity/Q40537266
Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers.Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients.Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin.Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects.Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact.Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
P2860

Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.

Item
http://www.wikidata.org/entity/Q40537266
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Impact of Venetoclax Exposure ...... Chronic Lymphocytic Leukemia.
@en
type
label
Impact of Venetoclax Exposure ...... Chronic Lymphocytic Leukemia.
@en
prefLabel
Impact of Venetoclax Exposure ...... Chronic Lymphocytic Leukemia.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P921
P356
P1433
P1476
Impact of Venetoclax Exposure ...... Chronic Lymphocytic Leukemia.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P921